ClinicalTrials.gg
CompletedNCT03570749BRAVE-AA1Updated Apr 16, 2026Results posted

A Study of Baricitinib (LY3009104) in Participants With Severe or Very Severe Alopecia Areata

A Phase 2/3 interventional study of Baricitinib and Placebo in Alopecia Areata, sponsored by Eli Lilly and Company. Completed at 75 sites in 5 countries. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-04-16.

Sponsored by Eli Lilly and Company · Phase 2/3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
784
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 98 studies in Alopecia Areata with a site in United States — 21 open to participants now, 32 under way, 8 of them phase 3. Alopecia Areata · United States.

Enrollment
4th of 84
784 · median 46
Started
2018
with 5 others
Phase 2/3
4 of 98
none open now
Registered
37th of 98
by date
Lead sponsor
3 of 98
Eli Lilly and Company

Among the 98 studies in Alopecia Areata with a site in United States, this one is the 4th largest by enrollment of the 84 interventional ones that give a count, is one of 6 that started in 2018, is one of 4 in phase 2/3, and was the 37th registered.

Alopecia Areata

220 studies on the registry are indexed under Alopecia Areata; 61 are open to participants now.

Browse Alopecia Areata studies →

Open to participants now

21 of the 98 studies in Alopecia Areata with a site in United States are open now. Recruiting first, the newest first:

16 more — sign in →

All 21 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 41 Alopecia Areata studies recruiting now, 16 (39%) set no upper age limit and 21 (51%) stop at 75 or younger; 20 take children under 18; 5 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 98 studies in Alopecia Areata with a site in United States, or all of them as a file.
02

Study summary

This study is designed to select up to two doses of baricitinib (referred to as low dose and high dose) and assess their efficacy and safety for the treatment of severe or very severe alopecia areata. An additional subpopulation of 60 participants in the US will enroll in the open-label addenda.

03

Conditions studied

  • Alopecia Areata

Browse trials for

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Are at least 18 years and ≤60 years for males (≤70 years of age for females) at the time of .
  • Must self-identify as either Black or African American in race in the open label addenda.
  • Have severe or very severe AA, as determined by all of the following:

    • Current AA episode of more than 6 months' duration and hair loss encompassing ≥50% of the scalp, as measured by -- Severity of Alopecia Tool (SALT) Alopecia Areata (AA) Investigator Global Assessment (AA-IGA) of 3 or 4) at screening and baseline.
    • No spontaneous improvement over the past 6 months.
    • Current episode of severe or very severe AA of less than 8 years.
    • Male or nonpregnant, nonbreastfeeding female participants.

Exclusion criteria

Exclusion Criteria:

  • Primarily "diffuse" type of AA.
  • Are currently experiencing other forms of alopecia or any other concomitant conditions that would interfere with evaluations of the effect of study medication on AA.
  • Previously treated with an oral Janus kinase (JAK) inhibitor and had an inadequate response (for example, absence of significant terminal hair growth after at least 12 weeks of treatment).
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
784 participants (actual)

Study arms

  • Placebo comparator
    Placebo Phase 2

    Participants received three placebo tablets administered orally once daily (QD). Rescue therapy with Baricitinib 2 mg or 4 mg was provided to participants who failed to achieve Severity of Alopecia Tool (SALT) ≤20 (less than or equal to 20) during the study period.

    Drug: Baricitinib · Drug: Placebo

  • Experimental
    1 Milligram (mg) / 4 mg Baricitinib Phase 2

    Participants received one 1 mg baricitinib tablet administered orally QD and two placebo tablets administered orally QD to maintain the blind through Week 12. Following the decision point at Week 12, participants were transitioned to receive one 4 mg baricitinib tablet administered orally QD and two placebo tablets administered orally QD to maintain the blind, and continued treatment through Week 200.

    Drug: Baricitinib

  • Experimental
    2 mg Baricitinib Phase 2

    Participants received one 2 mg Baricitinib tablet administered orally QD, and two placebo tablets administered orally QD to maintain the blind.

    Drug: Baricitinib

  • Experimental
    4 mg Baricitinib Phase 2

    Participants received one 4 mg Baricitinib tablet administered orally, QD and two placebo tablets QD administered orally to maintain the blind.

    Drug: Baricitinib

  • Placebo comparator
    Placebo Phase 3

    Participants received two placebo tablets administered orally QD. Rescue therapy with Baricitinib 2 mg or 4 mg was provided to participants who failed to achieve SALT≤20 during this treatment period.

    Drug: Baricitinib · Drug: Placebo

  • Experimental
    2 mg Baricitinib Phase 3

    Participants received one 2 mg Baricitinib tablet administered orally QD, and one placebo tablet administered orally QD to maintain the blind.

    Drug: Baricitinib

  • Experimental
    4 mg Baricitinib Phase 3

    Participants received one 4 mg Baricitinib tablet administered orally QD, and one placebo tablet administered orally QD to maintain the blind.

    Drug: Baricitinib

  • Placebo comparator
    Placebo/ Placebo Phase 3

    Participants who received two placebo tablets administered orally QD in Period 1 continue to receive the same placebo in Period 2.

    Drug: Placebo

  • Experimental
    Placebo/ 2 mg Baricitinib Phase 3

    Participants who received Placebo at Period 1 switched to receive 2 mg Baricitinib dose administered orally QD in Period 2.

    Drug: Baricitinib

  • Experimental
    Placebo/ 4 mg Baricitinib Phase 3

    Participants who received Placebo at Period 1 switched to receive 4 mg Baricitinib dose administered orally QD in Period 2.

    Drug: Baricitinib

  • Experimental
    2 mg Baricitinib /2 mg Baricitinib Phase 3

    Participants who received 2 mg Baricitinib at Period 1 continued to receive 2 mg Baricitinib dose administered orally QD in Period 2.

    Drug: Baricitinib

  • Experimental
    2 mg Baricitinib /4 mg Baricitinib Phase 3

    Participants who received 2 mg Baricitinib at Period 1 switched to receive 4 mg Baricitinib dose administered orally QD in Period 2.

    Drug: Baricitinib

  • Experimental
    2 mg Baricitinib / Placebo Phase 3

    Participants who received 2 mg Baricitinib at Period 1 switched to receive Placebo administered orally QD in Period 2.

    Drug: Placebo

  • Experimental
    4 mg Baricitinib / Placebo Phase 3

    Participants who received 4 mg Baricitinib at Period 1 switched to receive Placebo administered orally QD in Period 2.

    Drug: Placebo

  • Experimental
    4 mg Baricitinib /4 mg Baricitinib Phase 3

    Participants who received 4 mg Baricitinib at Period 1 continued to receive 4 mg Baricitinib administered orally QD in Period 2.

    Drug: Baricitinib

  • Experimental
    4 mg Baricitinib Phase 3 Open-Label Addendum

    Participants who received one 4 mg Baricitinib tablet administered orally QD.

    Drug: Baricitinib

Interventions

  • Administered orally.

    Also known as: LY3009104

  • DrugPlacebo

    Administered orally.

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Achieving Severity of Alopecia Tool (SALT) ≤ 20 - Phase 3

    The SALT uses a visual aid showing the division of the scalp hair into 4 areas with the top of the head constituting 40% of total surface, the posterior/back of head 24%, right side and left side of head 18% each. The percentage of hair loss in each area is determined and is multiplied by the percentage of scalp covered by that area. The total sum of the 4 products of each area will give the SALT score, as developed by the National Alopecia Areata Foundation Working Committee. Only terminal hair is included in the SALT; vellus hair or any fine downy hair is not taken into account in the SALT scoring process. The SALT score will range from 0% to 100%, with lower score indicating better health outcomes.

    Time frame: Week 36

  2. Percent Change From Baseline in SALT Score - Phase 3 Open-Label Addendum

    The SALT uses a visual aid showing the division of the scalp hair into 4 areas with the top of the head constituting 40% of total surface, the posterior/back of head 24%, right side and left side of head 18% each. The percentage of hair loss in each area is determined and is multiplied by the percentage of scalp covered by that area. The total sum of the 4 products of each area will give the SALT score, as developed by the National Alopecia Areata Foundation Working Committee. Only terminal hair is included in the SALT; vellus hair or any fine downy hair is not taken into account in the SALT scoring process. The SALT score will range from 0% to 100, with lower score indicating better health outcomes.

    Time frame: Baseline, Week 52

Secondary outcomes

  1. Percent Change From Baseline in SALT Score - Phase 3

    The SALT uses a visual aid showing the division of the scalp hair into 4 areas with the top of the head constituting 40% of total surface, the posterior/back of head 24%, right side and left side of head 18% each. The percentage of hair loss in each area is determined and is multiplied by the percentage of scalp covered by that area. The total sum of the 4 products of each area will give the SALT score, as developed by the National Alopecia Areata Foundation Working Committee. Only terminal hair is included in the SALT; vellus hair or any fine downy hair is not taken into account in the SALT scoring process. The SALT score will range from 0% to 100, with lower score indicating better health outcomes. Least Squares Mean (LSM) was calculated using analysis of covariance (ANCOVA) with geographic region duration of current episode at baseline (\< 4 years versus ≥4 years), treatment group, and baseline value in the model.

    Time frame: Baseline, Week 36

  2. Percentage of Participants Achieving 50% Improvement of SALT (SALT50) - Phase 3

    SALT uses a visual aid showing the division of the scalp hair into 4 areas with the top of the head constituting 40% of total surface, the posterior/back of head 24%, right side and left side of head 18% each. The percentage of hair loss in each area is determined and is multiplied by the percentage of scalp covered by that area. The total sum of the 4 products of each area will give the SALT score, as developed by the National Alopecia Areata Foundation Working Committee. Only terminal hair is included in the SALT; vellus hair or any fine downy hair is not taken into account in the SALT scoring process . The SALT score will range from 0% to 100%. with lower score indicating better health outcomes.

    Time frame: Week 12

  3. Time for Participants to Achieve SALT ≤ 20 at Week 36 - Phase 3

    The SALT uses a visual aid showing the division of the scalp hair into 4 areas with the top of the head constituting 40% of total surface, the posterior/back of head 24%, right side and left side of head 18% each. The percentage of hair loss in each area is determined and is multiplied by the percentage of scalp covered by that area. The total sum of the 4 products of each area will give the SALT score, as developed by the National Alopecia Areata Foundation Working Committee. Only terminal hair is included in the SALT; vellus hair or any fine downy hair is not taken into account in the SALT scoring process. The SALT score will range from 0% to 100%, with lower score indicating better health outcomes. Kaplan-Meier method was used for analysis. Time for participants to achieve salt ≤ 20 at week 36 were reported in this outcome measure.

    Time frame: Week 36

  4. Percentage of Participants Achieving Clinician Reported Outcome (ClinRO) Measure for Eyebrow (EB) Hair Loss 0 or 1 With ≥ 2-point Improvement From Baseline (Among Participants With ClinRO Measure for EB Hair Loss ≥ 2 at Baseline) - Phase 3

    ClinRO is a clinician reported assessment which measures a participant's EB hair loss. It is comprised of 4 category response options: 0 = EB have full coverage and no areas of hair loss; 1 = There are minimal gaps in EB hair and distribution is even; 2 = There are significant gaps in EB hair or distribution is not even; 3 = No notable EB.

    Time frame: Week 36

  5. Percentage of Participants Achieving ClinRO Measure for Eyelash (EL) Hair Loss 0 or 1 With ≥ 2-point Improvement From Baseline (Among Participants With ClinRO Measure for EL Hair Loss ≥ 2 at Baseline) - Phase 3

    ClinRO measure for EL hair loss is comprised of 4 category response options: 0 = The EL form a continuous line along the eyelids on both eyes; 1 = There are minimal gaps and the EL are evenly spaced along the eyelids on both eyes; 2 = There are significant gaps along the eyelids or the EL are not evenly spaced along the eyelids; 3 = No notable EL.

    Time frame: Week 36

  6. Percentage of Participants With Patient Reported Outcome (PRO) for Scalp Hair Assessment Score of 0 or 1 With a ≥ 2 Point Improvement From Baseline Among Participants With a Score of ≥ 3 at Baseline - Phase 3

    PRO is an assessment of the participant's current extent of scalp involvement. It is comprised of 5 category response options: 0= No missing hair (0% of my scalp is missing hair; I have a full head of hair); 1 = A limited area (1% to 20% of my scalp is missing hair); 2 = A moderate area (21% to 49% of my scalp is missing hair); 3 = A large area (50% to 94% of my scalp is missing hair); and 4 = Nearly all or all (95% to 100% of my scalp is missing hair).

    Time frame: Week 36

  7. Percentage of Participants Achieving PRO Measure for EB 0 or 1 With ≥ 2-point Improvement From Baseline (Among Participants With PRO Measure for EB ≥ 2 at Baseline) - Phase 3

    PRO is an assessment of the participant's current appearance of eyebrows. It is comprised of 4 category response options: 0 = I have full EB on each eye; 1= I have a minimal gap(s) or a minimal amount of thinning in at least 1 of my EB; 2 = I have a large gap(s) or a large amount of thinning in at least 1 of my EB; and 3 = I have no or barely any EB hairs.

    Time frame: Week 36

  8. Percentage of Participants Achieving PRO Measure for EL 0 or 1 With ≥ 2-point Improvement From Baseline (Among Participants With PRO Measure EL ≥2 at Baseline) - Phase 3

    PRO assessment of the participant's current appearance of EL. It is comprised of 4 category response options: 0 = I have full EL on each eyelid; 1 = I have a minimal gap or minimal gaps along the eyelids; 2 = I have a large gap or large gaps along the eyelids; and 3 = I have no or barely any EL hair.

    Time frame: Week 36

  9. Mean Change From Baseline in Hospital Anxiety Depression Scale (HADS) Anxiety Score - Phase 3

    The Hospital Anxiety Depression Scale (HADS) is a 14 item self-assessment scale that determines the levels of anxiety and depression that a patient is experiencing over the past week. The HADS utilizes a 4-point Likert scale (e.g., 0 to 3) for each question and is intended for ages 12 to 65 years. Scores for each domain (anxiety and depression) can range from 0 to 21, with higher scores indicating greater anxiety or depression. LS mean was calculated using an ANCOVA model which includes geographic region, duration of current episode at baseline (\<4 years vs. ≥4 years), treatment group and baseline score as fixed factors.

    Time frame: Baseline, Week 36

  10. Mean Change From Baseline in HADS Depression Score - Phase 3

    The HADS is a 14 item self-assessment scale that determines the levels of anxiety and depression that a patient is experiencing over the past week. The HADS utilizes a 4-point Likert scale (e.g., 0 to 3) for each question and is intended for ages 12 to 65 years. Scores for each domain (anxiety and depression) can range from 0 to 21, with higher scores indicating greater anxiety or depression. LS mean was calculated using an ANCOVA model which includes geographic region, duration of current episode at baseline (\<4 years vs. ≥4 years), treatment group and baseline score as fixed factors.

    Time frame: Baseline, Week 36

  11. Percentage of Participants Achieving SALT ≤ 20 - Phase 3 Open-Label Addendum

    The SALT uses a visual aid showing the division of the scalp hair into 4 areas with the top of the head constituting 40% of total surface, the posterior/back of head 24%, right side and left side of head 18% each. The percentage of hair loss in each area is determined and is multiplied by the percentage of scalp covered by that area. The total sum of the 4 products of each area will give the SALT score, as developed by the National Alopecia Areata Foundation Working Committee. Only terminal hair is included in the SALT; vellus hair or any fine downy hair is not taken into account in the SALT scoring process. The SALT score will range from 0% to 100%, with lower score indicating better health outcomes.

    Time frame: Week 52

  12. Percentage of Participants Achieving 50% Improvement of SALT (SALT50) - Phase 3 Open-Label Addendum

    SALT uses a visual aid showing the division of the scalp hair into 4 areas with the top of the head constituting 40% of total surface, the posterior/back of head 24%, right side and left side of head 18% each. The percentage of hair loss in each area is determined and is multiplied by the percentage of scalp covered by that area. The total sum of the 4 products of each area will give the SALT score, as developed by the National Alopecia Areata Foundation Working Committee. Only terminal hair is included in the SALT; vellus hair or any fine downy hair is not taken into account in the SALT scoring process . The SALT score will range from 0% to 100%. with lower score indicating better health outcomes.

    Time frame: Week 52

  13. Percentage of Participants Achieving ClinRO Measure for Eyebrow (EB) Hair Loss 0 or 1 With ≥ 2-point Improvement From Baseline (Among Participants With ClinRO Measure for EB Hair Loss ≥ 2 at Baseline) - Phase 3 Open-Label Addendum

    ClinRO is a clinician reported assessment which measures a participant's EB hair loss. It is comprised of 4 category response options: 0 = EB have full coverage and no areas of hair loss; 1 = There are minimal gaps in EB hair and distribution is even; 2 = There are significant gaps in EB hair or distribution is not even; 3 = No notable EB.

    Time frame: Week 52

  14. Percentage of Participants Achieving ClinRO Measure for Eyelash (EL) Hair Loss 0 or 1 With ≥ 2-point Improvement From Baseline (Among Participants With ClinRO Measure for EL Hair Loss ≥ 2 at Baseline) - Phase 3 Open-Label Addendum

    ClinRO measure for EL hair loss is comprised of 4 category response options: 0 = The EL form a continuous line along the eyelids on both eyes; 1 = There are minimal gaps and the EL are evenly spaced along the eyelids on both eyes; 2 = There are significant gaps along the eyelids or the EL are not evenly spaced along the eyelids; 3 = No notable EL.

    Time frame: Week 52

  15. Percentage of Participants With Patient Reported Outcome (PRO) for Scalp Hair Assessment Score of 0 or 1 With a ≥ 2 Point Improvement From Baseline Among Participants With a Score of ≥ 3 at Baseline - Phase 3 Open-Label Addendum

    PRO is an assessment of the participant's current extent of scalp involvement. It is comprised of 5 category response options: 0= No missing hair (0% of my scalp is missing hair; I have a full head of hair); 1 = A limited area (1% to 20% of my scalp is missing hair); 2 = A moderate area (21% to 49% of my scalp is missing hair); 3 = A large area (50% to 94% of my scalp is missing hair); and 4 = Nearly all or all (95% to 100% of my scalp is missing hair).

    Time frame: Week 52

07

Results

Posted Oct 1, 2025

Participant flow

The study was conducted in three separate parts with no participant overlap: • Phase 2 (Weeks 0-200): Participants completed 12 weeks of treatment or early discontinuation. At Week 12, an interim analysis was conducted to determine doses for Phase 3. Based on these Phase 2 interim results, subsequent participants in Phase 3 were enrolled and assigned to receive either baricitinib 2 mg or 4 mg.

Phase 2 Period (Week 0 to Week 200)
Participant flow — Phase 2 Period (Week 0 to Week 200)
MilestonePlacebo Phase 21 Milligram (mg) / 4 mg Baricitinib Phase 22 mg Baricitinib Phase 24 mg Baricitinib Phase 2Placebo Phase 32 mg Baricitinib Phase 34 mg Baricitinib Phase 3Placebo/ Placebo Phase 3Placebo/ 2 mg Baricitinib Phase 3Placebo/ 4 mg Baricitinib Phase 32 mg Baricitinib /2 mg Baricitinib Phase 32 mg Baricitinib /4 mg Baricitinib Phase 32 mg Baricitinib / Placebo Phase 34 mg Baricitinib / Placebo Phase 34 mg Baricitinib /4 mg Baricitinib Phase 34 mg Baricitinib Phase 3 Open-Label Addendum
Started28282727000000000000
Safety population28282727000000000000
All baricitinib phase 2 (combined baricitinib: 1 mg/4 mg, 2 mg and 4 mg) -safety population24282727000000000000
Completed10111516000000000000
Not completed18171211000000000000
Withdrew: Adverse event0001000000000000
Withdrew: Lack of efficacy1121000000000000
Withdrew: Lost to follow-up1611000000000000
Withdrew: Pregnancy1000000000000000
Withdrew: Withdrawal by subject8563000000000000
Withdrew: Protocol defined discontinuation criteria met at week 767425000000000000
Withdrew: Did not meet study criteria; out of range labs0100000000000000
Withdrew: Site procedural error; participant initiated commercial treatment0010000000000000
Phase 3 Period 1 (Week 0 to Week 52)
Participant flow — Phase 3 Period 1 (Week 0 to Week 52)
MilestonePlacebo Phase 21 Milligram (mg) / 4 mg Baricitinib Phase 22 mg Baricitinib Phase 24 mg Baricitinib Phase 2Placebo Phase 32 mg Baricitinib Phase 34 mg Baricitinib Phase 3Placebo/ Placebo Phase 3Placebo/ 2 mg Baricitinib Phase 3Placebo/ 4 mg Baricitinib Phase 32 mg Baricitinib /2 mg Baricitinib Phase 32 mg Baricitinib /4 mg Baricitinib Phase 32 mg Baricitinib / Placebo Phase 34 mg Baricitinib / Placebo Phase 34 mg Baricitinib /4 mg Baricitinib Phase 34 mg Baricitinib Phase 3 Open-Label Addendum
Started0000189184281000000000
Safety population0000189183280000000000
All baricitinib phase 3 (combined baricitinib: 2 mg and 4 mg) - safety population0000156183280000000000
Completed0000159163252000000000
Not completed0000302129000000000
Withdrew: Adverse event0000125000000000
Withdrew: Lack of efficacy0000202000000000
Withdrew: Lost to follow-up0000674000000000
Withdrew: Due to pandemic0000200000000000
Withdrew: Pregnancy0000001000000000
Withdrew: Withdrawal by subject0000171014000000000
Withdrew: Randomized, not treated0000001000000000
Withdrew: Lack of adherence0000100000000000
Withdrew: Non-compliant with protocol0000010000000000
Withdrew: Sponsor decision0000001000000000
Withdrew: Physician decision0000011000000000
Withdrew: Participant relocated and could not come to site visits0000100000000000
Phase 3 Period 2 (Week 52 to Week 248)
Participant flow — Phase 3 Period 2 (Week 52 to Week 248)
MilestonePlacebo Phase 21 Milligram (mg) / 4 mg Baricitinib Phase 22 mg Baricitinib Phase 24 mg Baricitinib Phase 2Placebo Phase 32 mg Baricitinib Phase 34 mg Baricitinib Phase 3Placebo/ Placebo Phase 3Placebo/ 2 mg Baricitinib Phase 3Placebo/ 4 mg Baricitinib Phase 32 mg Baricitinib /2 mg Baricitinib Phase 32 mg Baricitinib /4 mg Baricitinib Phase 32 mg Baricitinib / Placebo Phase 34 mg Baricitinib / Placebo Phase 34 mg Baricitinib /4 mg Baricitinib Phase 34 mg Baricitinib Phase 3 Open-Label Addendum
Started00000009767332121101091430
Completed0000000627372060729960
Not completed0000000349361261380470
Withdrew: Adverse event0000000041200140
Withdrew: Lack of efficacy0000000074240850
Withdrew: Lost to follow-up00000000531928120
Withdrew: Protocol defined discontinuation criteria met at week 7600000000221903605140
Withdrew: Physician decision0000000000100030
Withdrew: Pregnancy0000000000100000
Withdrew: Withdrawal by subject0000000396311011190
Withdrew: Other0000000011000000
Withdrew: Due to pandemic0000000000100000
Withdrew: Site closed0000000011000100
Withdrew: Protocol deviation0000000001100000
Withdrew: Due to time constraints and inability to attend required study visits0000000000010000
Withdrew: Met exclusion criteria0000000000001000
Phase 3 Open Label Addendum (Week 0-52)
Participant flow — Phase 3 Open Label Addendum (Week 0-52)
MilestonePlacebo Phase 21 Milligram (mg) / 4 mg Baricitinib Phase 22 mg Baricitinib Phase 24 mg Baricitinib Phase 2Placebo Phase 32 mg Baricitinib Phase 34 mg Baricitinib Phase 3Placebo/ Placebo Phase 3Placebo/ 2 mg Baricitinib Phase 3Placebo/ 4 mg Baricitinib Phase 32 mg Baricitinib /2 mg Baricitinib Phase 32 mg Baricitinib /4 mg Baricitinib Phase 32 mg Baricitinib / Placebo Phase 34 mg Baricitinib / Placebo Phase 34 mg Baricitinib /4 mg Baricitinib Phase 34 mg Baricitinib Phase 3 Open-Label Addendum
Started00000000000000020
Safety population00000000000000019
Completed00000000000000011
Not completed0000000000000009
Withdrew: Lost to follow-up0000000000000003
Withdrew: Randomized but not treated0000000000000001
Withdrew: Withdrawal by subject0000000000000005

Outcome measures

PrimaryPercentage of Participants Achieving Severity of Alopecia Tool (SALT) ≤ 20 - Phase 3

The SALT uses a visual aid showing the division of the scalp hair into 4 areas with the top of the head constituting 40% of total surface, the posterior/back of head 24%, right side and left side of head 18% each. The percentage of hair loss in each area is determined and is multiplied by the percentage of scalp covered by that area. The total sum of the 4 products of each area will give the SALT score, as developed by the National Alopecia Areata Foundation Working Committee. Only terminal hair is included in the SALT; vellus hair or any fine downy hair is not taken into account in the SALT scoring process. The SALT score will range from 0% to 100%, with lower score indicating better health outcomes.

Time frame:
Week 36
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Severity of Alopecia Tool (SALT) ≤ 20 - Phase 3
percentage of participantsPlacebo Phase 32 mg Baricitinib Phase 34 mg Baricitinib Phase 3
Percentage of Participants Achieving Severity of Alopecia Tool (SALT) ≤ 20 - Phase 35.3 (2.9 to 9.5)21.7 (16.4 to 28.2)35.2 (29.9 to 41.0)
Statistical analysis
  • Placebo Phase 3 vs 2 mg Baricitinib Phase 3 · Regression, Logistic · p = <0.001 · Odds ratio (or): 5.75 · 95% CI 2.75 to 12.02
  • Placebo Phase 3 vs 4 mg Baricitinib Phase 3 · Regression, Logistic · p = <0.001 · Odds ratio (or): 11.80 · 95% CI 5.89 to 23.62
PrimaryPercent Change From Baseline in SALT Score - Phase 3 Open-Label Addendum

The SALT uses a visual aid showing the division of the scalp hair into 4 areas with the top of the head constituting 40% of total surface, the posterior/back of head 24%, right side and left side of head 18% each. The percentage of hair loss in each area is determined and is multiplied by the percentage of scalp covered by that area. The total sum of the 4 products of each area will give the SALT score, as developed by the National Alopecia Areata Foundation Working Committee. Only terminal hair is included in the SALT; vellus hair or any fine downy hair is not taken into account in the SALT scoring process. The SALT score will range from 0% to 100, with lower score indicating better health outcomes.

Time frame:
Baseline, Week 52
Reported as:
Mean · percent change
Percent Change From Baseline in SALT Score - Phase 3 Open-Label Addendum
percent change4 mg Baricitinib Phase 3 Open-Label Addendum
Percent Change From Baseline in SALT Score - Phase 3 Open-Label Addendum-40.44 ± 33.182
SecondaryPercent Change From Baseline in SALT Score - Phase 3

The SALT uses a visual aid showing the division of the scalp hair into 4 areas with the top of the head constituting 40% of total surface, the posterior/back of head 24%, right side and left side of head 18% each. The percentage of hair loss in each area is determined and is multiplied by the percentage of scalp covered by that area. The total sum of the 4 products of each area will give the SALT score, as developed by the National Alopecia Areata Foundation Working Committee. Only terminal hair is included in the SALT; vellus hair or any fine downy hair is not taken into account in the SALT scoring process. The SALT score will range from 0% to 100, with lower score indicating better health outcomes. Least Squares Mean (LSM) was calculated using analysis of covariance (ANCOVA) with geographic region duration of current episode at baseline (\< 4 years versus ≥4 years), treatment group, and baseline value in the model.

Time frame:
Baseline, Week 36
Reported as:
Least squares mean · percent change
Percent Change From Baseline in SALT Score - Phase 3
percent changePlacebo Phase 32 mg Baricitinib Phase 34 mg Baricitinib Phase 3
Percent Change From Baseline in SALT Score - Phase 3-8.13 ± 3.100-31.23 ± 3.157-45.79 ± 2.663
Statistical analysis
  • Placebo Phase 3 vs 2 mg Baricitinib Phase 3 · ANCOVA · p = <0.001 · Mean difference (final values): -23.10 · 95% CI -30.57 to -15.63
  • Placebo Phase 3 vs 4 mg Baricitinib Phase 3 · ANCOVA · p = <0.001 · Mean difference (final values): -37.65 · 95% CI -44.24 to -30.89
SecondaryPercentage of Participants Achieving 50% Improvement of SALT (SALT50) - Phase 3

SALT uses a visual aid showing the division of the scalp hair into 4 areas with the top of the head constituting 40% of total surface, the posterior/back of head 24%, right side and left side of head 18% each. The percentage of hair loss in each area is determined and is multiplied by the percentage of scalp covered by that area. The total sum of the 4 products of each area will give the SALT score, as developed by the National Alopecia Areata Foundation Working Committee. Only terminal hair is included in the SALT; vellus hair or any fine downy hair is not taken into account in the SALT scoring process . The SALT score will range from 0% to 100%. with lower score indicating better health outcomes.

Time frame:
Week 12
Reported as:
Number · percentage of participants
Percentage of Participants Achieving 50% Improvement of SALT (SALT50) - Phase 3
percentage of participantsPlacebo Phase 32 mg Baricitinib Phase 34 mg Baricitinib Phase 3
Percentage of Participants Achieving 50% Improvement of SALT (SALT50) - Phase 34.8 (2.5 to 8.8)9.8 (6.3 to 14.9)21.7 (17.3 to 26.9)
Statistical analysis
  • Placebo Phase 3 vs 2 mg Baricitinib Phase 3 · Regression, Logistic · p = 0.047 · Odds ratio (or): 2.31 · 95% CI 1.01 to 5.29
  • Placebo Phase 3 vs 4 mg Baricitinib Phase 3 · Regression, Logistic · p = <0.001 · Odds ratio (or): 6.03 · 95% CI 2.91 to 12.51
SecondaryTime for Participants to Achieve SALT ≤ 20 at Week 36 - Phase 3

The SALT uses a visual aid showing the division of the scalp hair into 4 areas with the top of the head constituting 40% of total surface, the posterior/back of head 24%, right side and left side of head 18% each. The percentage of hair loss in each area is determined and is multiplied by the percentage of scalp covered by that area. The total sum of the 4 products of each area will give the SALT score, as developed by the National Alopecia Areata Foundation Working Committee. Only terminal hair is included in the SALT; vellus hair or any fine downy hair is not taken into account in the SALT scoring process. The SALT score will range from 0% to 100%, with lower score indicating better health outcomes. Kaplan-Meier method was used for analysis. Time for participants to achieve salt ≤ 20 at week 36 were reported in this outcome measure.

Time frame:
Week 36
Reported as:
Median · Days
Time for Participants to Achieve SALT ≤ 20 at Week 36 - Phase 3
DaysPlacebo Phase 32 mg Baricitinib Phase 34 mg Baricitinib Phase 3
Time for Participants to Achieve SALT ≤ 20 at Week 36 - Phase 3NA (NA to NA)NA (NA to NA)NA (NA to NA)
SecondaryPercentage of Participants Achieving Clinician Reported Outcome (ClinRO) Measure for Eyebrow (EB) Hair Loss 0 or 1 With ≥ 2-point Improvement From Baseline (Among Participants With ClinRO Measure for EB Hair Loss ≥ 2 at Baseline) - Phase 3

ClinRO is a clinician reported assessment which measures a participant's EB hair loss. It is comprised of 4 category response options: 0 = EB have full coverage and no areas of hair loss; 1 = There are minimal gaps in EB hair and distribution is even; 2 = There are significant gaps in EB hair or distribution is not even; 3 = No notable EB.

Time frame:
Week 36
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Clinician Reported Outcome (ClinRO) Measure for Eyebrow (EB) Hair Loss 0 or 1 With ≥ 2-point Improvement From Baseline (Among Participants With ClinRO Measure for EB Hair Loss ≥ 2 at Baseline) - Phase 3
percentage of participantsPlacebo Phase 32 mg Baricitinib Phase 34 mg Baricitinib Phase 3
Percentage of Participants Achieving Clinician Reported Outcome (ClinRO) Measure for Eyebrow (EB) Hair Loss 0 or 1 With ≥ 2-point Improvement From Baseline (Among Participants With ClinRO Measure for EB Hair Loss ≥ 2 at Baseline) - Phase 33.2 (1.3 to 8.0)19.1 (13.4 to 26.5)31.4 (25.2 to 38.3)
Statistical analysis
  • Placebo Phase 3 vs 2 mg Baricitinib Phase 3 · Regression, Logistic · p = <0.001 · Odds ratio (or): 6.60 · 95% CI 2.34 to 18.62
  • Placebo Phase 3 vs 4 mg Baricitinib Phase 3 · Regression, Logistic · p = <0.001 · Odds ratio (or): 13.58 · 95% CI 5.01 to 36.81
SecondaryPercentage of Participants Achieving ClinRO Measure for Eyelash (EL) Hair Loss 0 or 1 With ≥ 2-point Improvement From Baseline (Among Participants With ClinRO Measure for EL Hair Loss ≥ 2 at Baseline) - Phase 3

ClinRO measure for EL hair loss is comprised of 4 category response options: 0 = The EL form a continuous line along the eyelids on both eyes; 1 = There are minimal gaps and the EL are evenly spaced along the eyelids on both eyes; 2 = There are significant gaps along the eyelids or the EL are not evenly spaced along the eyelids; 3 = No notable EL.

Time frame:
Week 36
Reported as:
Number · percentage of participants
Percentage of Participants Achieving ClinRO Measure for Eyelash (EL) Hair Loss 0 or 1 With ≥ 2-point Improvement From Baseline (Among Participants With ClinRO Measure for EL Hair Loss ≥ 2 at Baseline) - Phase 3
percentage of participantsPlacebo Phase 32 mg Baricitinib Phase 34 mg Baricitinib Phase 3
Percentage of Participants Achieving ClinRO Measure for Eyelash (EL) Hair Loss 0 or 1 With ≥ 2-point Improvement From Baseline (Among Participants With ClinRO Measure for EL Hair Loss ≥ 2 at Baseline) - Phase 33.1 (1.1 to 8.8)13.5 (8.4 to 21.1)33.5 (26.8 to 41.0)
Statistical analysis
  • Placebo Phase 3 vs 2 mg Baricitinib Phase 3 · Regression, Logistic · p = 0.012 · Odds ratio (or): 4.63 · 95% CI 1.41 to 15.27
  • Placebo Phase 3 vs 4 mg Baricitinib Phase 3 · Regression, Logistic · p = <0.001 · Odds ratio (or): 14.42 · 95% CI 4.73 to 43.93
SecondaryPercentage of Participants With Patient Reported Outcome (PRO) for Scalp Hair Assessment Score of 0 or 1 With a ≥ 2 Point Improvement From Baseline Among Participants With a Score of ≥ 3 at Baseline - Phase 3

PRO is an assessment of the participant's current extent of scalp involvement. It is comprised of 5 category response options: 0= No missing hair (0% of my scalp is missing hair; I have a full head of hair); 1 = A limited area (1% to 20% of my scalp is missing hair); 2 = A moderate area (21% to 49% of my scalp is missing hair); 3 = A large area (50% to 94% of my scalp is missing hair); and 4 = Nearly all or all (95% to 100% of my scalp is missing hair).

Time frame:
Week 36
Reported as:
Number · percentage of participants
Percentage of Participants With Patient Reported Outcome (PRO) for Scalp Hair Assessment Score of 0 or 1 With a ≥ 2 Point Improvement From Baseline Among Participants With a Score of ≥ 3 at Baseline - Phase 3
percentage of participantsPlacebo Phase 32 mg Baricitinib Phase 34 mg Baricitinib Phase 3
Percentage of Participants With Patient Reported Outcome (PRO) for Scalp Hair Assessment Score of 0 or 1 With a ≥ 2 Point Improvement From Baseline Among Participants With a Score of ≥ 3 at Baseline - Phase 35.0 (2.6 to 9.2)16.0 (11.3 to 22.2)33.1 (27.8 to 38.9)
Statistical analysis
  • Placebo Phase 3 vs 2 mg Baricitinib Phase 3 · Regression, Logistic · p = <0.001 · Odds ratio (or): 3.92 · 95% CI 1.81 to 8.51
  • Placebo Phase 3 vs 4 mg Baricitinib Phase 3 · Regression, Logistic · p = <0.001 · Odds ratio (or): 10.26 · 95% CI 5.05 to 20.87
SecondaryPercentage of Participants Achieving PRO Measure for EB 0 or 1 With ≥ 2-point Improvement From Baseline (Among Participants With PRO Measure for EB ≥ 2 at Baseline) - Phase 3

PRO is an assessment of the participant's current appearance of eyebrows. It is comprised of 4 category response options: 0 = I have full EB on each eye; 1= I have a minimal gap(s) or a minimal amount of thinning in at least 1 of my EB; 2 = I have a large gap(s) or a large amount of thinning in at least 1 of my EB; and 3 = I have no or barely any EB hairs.

Time frame:
Week 36
Reported as:
Number · percentage of participants
Percentage of Participants Achieving PRO Measure for EB 0 or 1 With ≥ 2-point Improvement From Baseline (Among Participants With PRO Measure for EB ≥ 2 at Baseline) - Phase 3
percentage of participantsPlacebo Phase 32 mg Baricitinib Phase 34 mg Baricitinib Phase 3
Percentage of Participants Achieving PRO Measure for EB 0 or 1 With ≥ 2-point Improvement From Baseline (Among Participants With PRO Measure for EB ≥ 2 at Baseline) - Phase 33.1 (1.2 to 7.6)16.3 (11.1 to 23.3)32.1 (25.7 to 39.1)
Statistical analysis
  • Placebo Phase 3 vs 2 mg Baricitinib Phase 3 · Regression, Logistic · p = 0.001 · Odds ratio (or): 5.58 · 95% CI 1.97 to 15.83
  • Placebo Phase 3 vs 4 mg Baricitinib Phase 3 · Regression, Logistic · p = <0.001 · Odds ratio (or): 14.34 · 95% CI 5.30 to 38.83
SecondaryPercentage of Participants Achieving PRO Measure for EL 0 or 1 With ≥ 2-point Improvement From Baseline (Among Participants With PRO Measure EL ≥2 at Baseline) - Phase 3

PRO assessment of the participant's current appearance of EL. It is comprised of 4 category response options: 0 = I have full EL on each eyelid; 1 = I have a minimal gap or minimal gaps along the eyelids; 2 = I have a large gap or large gaps along the eyelids; and 3 = I have no or barely any EL hair.

Time frame:
Week 36
Reported as:
Number · percentage of participants
Percentage of Participants Achieving PRO Measure for EL 0 or 1 With ≥ 2-point Improvement From Baseline (Among Participants With PRO Measure EL ≥2 at Baseline) - Phase 3
percentage of participantsPlacebo Phase 32 mg Baricitinib Phase 34 mg Baricitinib Phase 3
Percentage of Participants Achieving PRO Measure for EL 0 or 1 With ≥ 2-point Improvement From Baseline (Among Participants With PRO Measure EL ≥2 at Baseline) - Phase 32.0 (0.6 to 7.0)19.6 (13.3 to 28.0)29.8 (23.3 to 37.3)
Statistical analysis
  • Placebo Phase 3 vs 2 mg Baricitinib Phase 3 · Regression, Logistic · p = <0.001 · Odds ratio (or): 10.34 · 95% CI 2.72 to 39.30
  • Placebo Phase 3 vs 4 mg Baricitinib Phase 3 · Regression, Logistic · p = <0.001 · Odds ratio (or): 18.47 · 95% CI 5.04 to 67.68
SecondaryMean Change From Baseline in Hospital Anxiety Depression Scale (HADS) Anxiety Score - Phase 3

The Hospital Anxiety Depression Scale (HADS) is a 14 item self-assessment scale that determines the levels of anxiety and depression that a patient is experiencing over the past week. The HADS utilizes a 4-point Likert scale (e.g., 0 to 3) for each question and is intended for ages 12 to 65 years. Scores for each domain (anxiety and depression) can range from 0 to 21, with higher scores indicating greater anxiety or depression. LS mean was calculated using an ANCOVA model which includes geographic region, duration of current episode at baseline (\<4 years vs. ≥4 years), treatment group and baseline score as fixed factors.

Time frame:
Baseline, Week 36
Reported as:
Least squares mean · score on a scale
Mean Change From Baseline in Hospital Anxiety Depression Scale (HADS) Anxiety Score - Phase 3
score on a scalePlacebo Phase 32 mg Baricitinib Phase 34 mg Baricitinib Phase 3
Mean Change From Baseline in Hospital Anxiety Depression Scale (HADS) Anxiety Score - Phase 3-0.40 ± 0.234-1.22 ± 0.236-0.93 ± 0.199
Statistical analysis
  • Placebo Phase 3 vs 2 mg Baricitinib Phase 3 · ANCOVA · p = 0.005 · Mean difference (final values): -0.82 · 95% CI -1.38 to -0.25
  • Placebo Phase 3 vs 4 mg Baricitinib Phase 3 · ANCOVA · p = 0.040 · Mean difference (final values): -0.54 · 95% CI -1.05 to -0.02
SecondaryMean Change From Baseline in HADS Depression Score - Phase 3

The HADS is a 14 item self-assessment scale that determines the levels of anxiety and depression that a patient is experiencing over the past week. The HADS utilizes a 4-point Likert scale (e.g., 0 to 3) for each question and is intended for ages 12 to 65 years. Scores for each domain (anxiety and depression) can range from 0 to 21, with higher scores indicating greater anxiety or depression. LS mean was calculated using an ANCOVA model which includes geographic region, duration of current episode at baseline (\<4 years vs. ≥4 years), treatment group and baseline score as fixed factors.

Time frame:
Baseline, Week 36
Reported as:
Least squares mean · score on a scale
Mean Change From Baseline in HADS Depression Score - Phase 3
score on a scalePlacebo Phase 32 mg Baricitinib Phase 34 mg Baricitinib Phase 3
Mean Change From Baseline in HADS Depression Score - Phase 30.04 ± 0.210-0.38 ± 0.213-0.28 ± 0.179
Statistical analysis
  • Placebo Phase 3 vs 2 mg Baricitinib Phase 3 · ANCOVA · p = 0.107 · Mean difference (final values): -0.42 · 95% CI -0.93 to 0.09
  • Placebo Phase 3 vs 4 mg Baricitinib Phase 3 · ANCOVA · p = 0.174 · Mean difference (final values): -0.32 · 95% CI -0.78 to 0.14
SecondaryPercentage of Participants Achieving SALT ≤ 20 - Phase 3 Open-Label Addendum

The SALT uses a visual aid showing the division of the scalp hair into 4 areas with the top of the head constituting 40% of total surface, the posterior/back of head 24%, right side and left side of head 18% each. The percentage of hair loss in each area is determined and is multiplied by the percentage of scalp covered by that area. The total sum of the 4 products of each area will give the SALT score, as developed by the National Alopecia Areata Foundation Working Committee. Only terminal hair is included in the SALT; vellus hair or any fine downy hair is not taken into account in the SALT scoring process. The SALT score will range from 0% to 100%, with lower score indicating better health outcomes.

Time frame:
Week 52
Reported as:
Number · percentage of participants
Percentage of Participants Achieving SALT ≤ 20 - Phase 3 Open-Label Addendum
percentage of participants4 mg Baricitinib Phase 3 Open-Label Addendum
Percentage of Participants Achieving SALT ≤ 20 - Phase 3 Open-Label Addendum18.2 (5.1 to 47.7)
SecondaryPercentage of Participants Achieving 50% Improvement of SALT (SALT50) - Phase 3 Open-Label Addendum

SALT uses a visual aid showing the division of the scalp hair into 4 areas with the top of the head constituting 40% of total surface, the posterior/back of head 24%, right side and left side of head 18% each. The percentage of hair loss in each area is determined and is multiplied by the percentage of scalp covered by that area. The total sum of the 4 products of each area will give the SALT score, as developed by the National Alopecia Areata Foundation Working Committee. Only terminal hair is included in the SALT; vellus hair or any fine downy hair is not taken into account in the SALT scoring process . The SALT score will range from 0% to 100%. with lower score indicating better health outcomes.

Time frame:
Week 52
Reported as:
Number · percentage of participants
Percentage of Participants Achieving 50% Improvement of SALT (SALT50) - Phase 3 Open-Label Addendum
percentage of participants4 mg Baricitinib Phase 3 Open-Label Addendum
Percentage of Participants Achieving 50% Improvement of SALT (SALT50) - Phase 3 Open-Label Addendum45.5 (21.3 to 72.0)
SecondaryPercentage of Participants Achieving ClinRO Measure for Eyebrow (EB) Hair Loss 0 or 1 With ≥ 2-point Improvement From Baseline (Among Participants With ClinRO Measure for EB Hair Loss ≥ 2 at Baseline) - Phase 3 Open-Label Addendum

ClinRO is a clinician reported assessment which measures a participant's EB hair loss. It is comprised of 4 category response options: 0 = EB have full coverage and no areas of hair loss; 1 = There are minimal gaps in EB hair and distribution is even; 2 = There are significant gaps in EB hair or distribution is not even; 3 = No notable EB.

Time frame:
Week 52
Reported as:
Number · percentage of participants
Percentage of Participants Achieving ClinRO Measure for Eyebrow (EB) Hair Loss 0 or 1 With ≥ 2-point Improvement From Baseline (Among Participants With ClinRO Measure for EB Hair Loss ≥ 2 at Baseline) - Phase 3 Open-Label Addendum
percentage of participants4 mg Baricitinib Phase 3 Open-Label Addendum
Percentage of Participants Achieving ClinRO Measure for Eyebrow (EB) Hair Loss 0 or 1 With ≥ 2-point Improvement From Baseline (Among Participants With ClinRO Measure for EB Hair Loss ≥ 2 at Baseline) - Phase 3 Open-Label Addendum50.0 (15.0 to 85.0)
SecondaryPercentage of Participants Achieving ClinRO Measure for Eyelash (EL) Hair Loss 0 or 1 With ≥ 2-point Improvement From Baseline (Among Participants With ClinRO Measure for EL Hair Loss ≥ 2 at Baseline) - Phase 3 Open-Label Addendum

ClinRO measure for EL hair loss is comprised of 4 category response options: 0 = The EL form a continuous line along the eyelids on both eyes; 1 = There are minimal gaps and the EL are evenly spaced along the eyelids on both eyes; 2 = There are significant gaps along the eyelids or the EL are not evenly spaced along the eyelids; 3 = No notable EL.

Time frame:
Week 52
Reported as:
Number · percentage of participants
Percentage of Participants Achieving ClinRO Measure for Eyelash (EL) Hair Loss 0 or 1 With ≥ 2-point Improvement From Baseline (Among Participants With ClinRO Measure for EL Hair Loss ≥ 2 at Baseline) - Phase 3 Open-Label Addendum
percentage of participants4 mg Baricitinib Phase 3 Open-Label Addendum
Percentage of Participants Achieving ClinRO Measure for Eyelash (EL) Hair Loss 0 or 1 With ≥ 2-point Improvement From Baseline (Among Participants With ClinRO Measure for EL Hair Loss ≥ 2 at Baseline) - Phase 3 Open-Label Addendum66.7 (20.8 to 93.9)
SecondaryPercentage of Participants With Patient Reported Outcome (PRO) for Scalp Hair Assessment Score of 0 or 1 With a ≥ 2 Point Improvement From Baseline Among Participants With a Score of ≥ 3 at Baseline - Phase 3 Open-Label Addendum

PRO is an assessment of the participant's current extent of scalp involvement. It is comprised of 5 category response options: 0= No missing hair (0% of my scalp is missing hair; I have a full head of hair); 1 = A limited area (1% to 20% of my scalp is missing hair); 2 = A moderate area (21% to 49% of my scalp is missing hair); 3 = A large area (50% to 94% of my scalp is missing hair); and 4 = Nearly all or all (95% to 100% of my scalp is missing hair).

Time frame:
Week 52
Reported as:
Number · percentage of participants
Percentage of Participants With Patient Reported Outcome (PRO) for Scalp Hair Assessment Score of 0 or 1 With a ≥ 2 Point Improvement From Baseline Among Participants With a Score of ≥ 3 at Baseline - Phase 3 Open-Label Addendum
percentage of participants4 mg Baricitinib Phase 3 Open-Label Addendum
Percentage of Participants With Patient Reported Outcome (PRO) for Scalp Hair Assessment Score of 0 or 1 With a ≥ 2 Point Improvement From Baseline Among Participants With a Score of ≥ 3 at Baseline - Phase 3 Open-Label Addendum20.0 (5.7 to 51.0)

Adverse events

Collected over Phase 2: Baseline up to Week 204 ; Phase 3: Baseline up to Week 252 ; Phase 3 Open-Label addendum : Baseline up to Week 56. (AE Description: As pre-specified in the SAP, AE were assessed using the "safety population". Given the sequential dose change within the Phase 2 Baricitinib 1 mg/4 mg Arm, it was not appropriate to attribute AEs to a single fixed dose, and therefore AEs were not collected separately. Also AE data were not collected separately for the Phase 3 Period 2 Arms.). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo Phase 20/28 (0%)0/28 (0%)12/28 (42.9%)
2 mg Baricitinib Phase 20/27 (0%)0/27 (0%)21/27 (77.8%)
4 mg Baricitinib Phase 20/27 (0%)2/27 (7.4%)19/27 (70.4%)
All Baricitinib Phase 2 (Combined Baricitinib: 1 mg/4 mg, 2 mg and 4 mg)0/106 (0%)3/106 (2.8%)79/106 (74.5%)
Placebo Phase 30/189 (0%)3/189 (1.6%)37/189 (19.6%)
2 mg Baricitinib Phase 30/183 (0%)7/183 (3.8%)58/183 (31.7%)
4 mg Baricitinib Phase 30/280 (0%)16/280 (5.7%)126/280 (45%)
All Baricitinib Phase 3 (Combined Baricitinib: 2 mg and 4 mg)0/619 (0%)40/619 (6.5%)275/619 (44.4%)
4 mg Baricitinib Phase 3 Open-Label Addendum0/19 (0%)1/19 (5.3%)13/19 (68.4%)
Most frequent serious events
Showing 10 of 48
Most frequent serious events
EventPlacebo Phase 22 mg Baricitinib Phase 24 mg Baricitinib Phase 2All Baricitinib Phase 2 (Combined Baricitinib: 1 mg/4 mg, 2 mg and 4 mg)Placebo Phase 32 mg Baricitinib Phase 34 mg Baricitinib Phase 3All Baricitinib Phase 3 (Combined Baricitinib: 2 mg and 4 mg)4 mg Baricitinib Phase 3 Open-Label Addendum
PriapismReproductive system and breast disorders0/120/40/20/250/800/750/1160/2591/5
Drug withdrawal syndromeGeneral disorders0/280/271/271/1060/1890/1830/2801/6190/19
DiverticulitisInfections and infestations0/280/271/271/1060/1890/1830/2800/6190/19
Thermal burnInjury, poisoning and procedural complications0/280/271/271/1060/1890/1830/2800/6190/19
Vaginal dysplasiaReproductive system and breast disorders0/160/230/251/810/1090/1080/1640/3600/14
Hand fractureInjury, poisoning and procedural complications0/280/270/270/1060/1892/1830/2802/6190/19
Hepatitis acuteHepatobiliary disorders0/280/270/270/1060/1890/1832/2802/6190/19
Craniofacial fractureInjury, poisoning and procedural complications0/280/270/270/1060/1890/1832/2802/6190/19
Abortion missedPregnancy, puerperium and perinatal conditions0/160/230/250/810/1090/1081/1641/3600/14
Acute myocardial infarctionCardiac disorders0/280/270/270/1060/1891/1830/2801/6190/19
Most frequent other events
Showing 10 of 42
Most frequent other events
EventPlacebo Phase 22 mg Baricitinib Phase 24 mg Baricitinib Phase 2All Baricitinib Phase 2 (Combined Baricitinib: 1 mg/4 mg, 2 mg and 4 mg)Placebo Phase 32 mg Baricitinib Phase 34 mg Baricitinib Phase 3All Baricitinib Phase 3 (Combined Baricitinib: 2 mg and 4 mg)4 mg Baricitinib Phase 3 Open-Label Addendum
Upper respiratory tract infectionInfections and infestations5/288/278/2732/10610/18917/18328/28063/6193/19
AcneSkin and subcutaneous tissue disorders0/282/273/278/1061/18913/18319/28049/6194/19
Covid-19Infections and infestations0/280/272/2715/1063/18918/18346/280130/6192/19
Urinary tract infectionInfections and infestations1/281/271/276/1064/1896/18316/28030/6193/19
NasopharyngitisInfections and infestations1/284/272/2714/10612/18913/18328/28048/6191/19
NeutropeniaBlood and lymphatic system disorders0/282/273/277/1060/1890/1830/2800/6192/19
NauseaGastrointestinal disorders0/282/273/278/1060/1890/1830/2800/6190/19
Oral herpesInfections and infestations1/283/271/276/1060/1890/1830/2800/6191/19
ArthralgiaMusculoskeletal and connective tissue disorders2/282/273/276/1060/1890/1830/2800/6190/19
Back painMusculoskeletal and connective tissue disorders3/283/271/274/1060/1890/1830/2800/6190/19

Baseline characteristics

All randomized participants from Phase 2, Phase 3, and the Phase 3 open-label addendum.

Age, Continuous
Age, Continuous(years)Placebo Phase 21 mg Baricitinib Phase 22 mg Baricitinib Phase 24 mg Baricitinib Phase 2Placebo Phase 32 mg Baricitinib Phase 34 mg Baricitinib Phase 34 mg Baricitinib Phase 3 Open-Label AddendumTotal
Mean40.5 ± 14.2338.6 ± 11.2642.5 ± 13.7542.4 ± 14.9137.4 ± 12.9138.0 ± 12.7836.3 ± 13.2746.0 ± 8.7537.8 ± 13.0
Sex: Female, Male
Sex: Female, Male(Participants)Placebo Phase 21 mg Baricitinib Phase 22 mg Baricitinib Phase 24 mg Baricitinib Phase 2Placebo Phase 32 mg Baricitinib Phase 34 mg Baricitinib Phase 34 mg Baricitinib Phase 3 Open-Label AddendumTotal
Female1618232510910916515480
Male12104280751165304
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Placebo Phase 21 mg Baricitinib Phase 22 mg Baricitinib Phase 24 mg Baricitinib Phase 2Placebo Phase 32 mg Baricitinib Phase 34 mg Baricitinib Phase 34 mg Baricitinib Phase 3 Open-Label AddendumTotal
American Indian or Alaska Native0001858022
Asian343478761140282
Native Hawaiian or Other Pacific Islander000011103
Black or African American4233177281983
White2122201983931230381
More than one race000011619
Unknown or Not Reported001011104
Region of Enrollment
Region of Enrollment(Participants)Placebo Phase 21 mg Baricitinib Phase 22 mg Baricitinib Phase 24 mg Baricitinib Phase 2Placebo Phase 32 mg Baricitinib Phase 34 mg Baricitinib Phase 34 mg Baricitinib Phase 3 Open-Label AddendumTotal
South Korea000070701070247
United States2525242410310215320476
Japan3333000012
Mexico0000161221049
Baseline Disease Severity of Alopecia Tool (SALT) Score
Baseline Disease Severity of Alopecia Tool (SALT) Score(units on a scale)Placebo Phase 21 mg Baricitinib Phase 22 mg Baricitinib Phase 24 mg Baricitinib Phase 2Placebo Phase 32 mg Baricitinib Phase 34 mg Baricitinib Phase 34 mg Baricitinib Phase 3 Open-Label AddendumTotal
Mean90.0 ± 15.6989.3 ± 17.6586.1 ± 19.3283.4 ± 17.5284.7 ± 17.8286.8 ± 18.0185.3 ± 18.1879.1 ± 21.2885.6 ± 17.5
08

Study locations

75 sites
  • University of Alabama at Birmingham
    Birmingham, Alabama 35233, United States
  • Coastal Clinical Research, Inc
    Mobile, Alabama 36608, United States
  • Johnson Dermatology
    Fort Smith, Arkansas 72916, United States
  • California Dermatology & Clinical Research Institute
    Encinitas, California 92024, United States
  • Alliance Research Centers
    Irvine, California 92612, United States
  • University of CA, Irvine
    Irvine, California 92617, United States
  • Dermatology Research Associates
    Los Angeles, California 90045, United States
  • Stanford Health Care
    Redwood City, California 94063, United States
  • University of California Davis-Dermatology
    Sacramento, California 95816, United States
  • University Clinical Trials, Inc.
    San Diego, California 92123, United States
  • Mosaic Dermatology
    Santa Monica, California 90403, United States
  • Yale University School of Medicine
    New Haven, Connecticut 06519, United States
  • Solutions Through Advanced Research, Inc.
    Jacksonville, Florida 32256, United States
  • University of Miami
    Miami, Florida 33125, United States
  • Park Avenue Dermatology
    Orange Park, Florida 32073, United States
  • ForCare Clinical Research
    Tampa, Florida 33613-1244, United States
  • Skin Care Physicians of Georgia
    Macon, Georgia 31217, United States
  • Medaphase Inc
    Newnan, Georgia 30263, United States
  • Northwestern University
    Chicago, Illinois 60611, United States
  • Forefront Research
    Louisville, Kentucky 40241, United States
  • Callender Center for Clinical Research, LLC / Research
    Glenn Dale, Maryland 20769, United States
  • ActivMed Practices and Research
    Beverly, Massachusetts 01915, United States
  • Massachusetts General Hospital
    Boston, Massachusetts 02114, United States
  • Brigham and Women's Hospital
    Boston, Massachusetts 02115, United States
  • Clarkston Skin Research
    Clarkston, Michigan 48346, United States
  • University of Minnesota Medical School
    Minneapolis, Minnesota 55455, United States
  • ActivMed Practices and Research
    Portsmouth, New Hampshire 03801, United States
  • University of Rochester School of Medicine
    Rochester, New York 14642, United States
  • Montefiore Medical Center
    The Bronx, New York 10467-2490, United States
  • University Hospitals Cleveland Medical Center
    Cleveland, Ohio 44106, United States
  • Cleveland Clinic Foundation
    Cleveland, Ohio 44195, United States
  • OH State Univ College of Med
    Gahanna, Ohio 43230, United States
  • NW Dermatology & Research Center, LLC
    Portland, Oregon 97210, United States
  • Oregon Medical Research Center
    Portland, Oregon 97223, United States
  • OHSU Center for Health and Healing
    Portland, Oregon 97239, United States
  • Dermatology and Skin Surgery Center
    Exton, Pennsylvania 19341, United States
  • Penn State Univ. Milton S. Hershey Medical Center
    Hershey, Pennsylvania 17033, United States
  • Perelman Center for Advanced Medicine
    Philadelphia, Pennsylvania 19104, United States
  • University of Pittsburgh Medical Center
    Pittsburgh, Pennsylvania 15213, United States
  • Dermatology Associates of Plymouth Meeting
    Plymouth Meeting, Pennsylvania 19462, United States
  • Medical University of South Carolina
    Charleston, South Carolina 29425, United States
  • Bellaire Dermatology
    Bellaire, Texas 77401, United States
  • Modern Research Associates
    Dallas, Texas 75231, United States
  • Center for Clinical Studies
    Houston, Texas 77004, United States
  • Austin Institute for Clinical Research
    Pflugerville, Texas 78660, United States
  • Texas Dermatology and Laser Specialists
    San Antonio, Texas 78218, United States
  • Dermatology Clinical Research Center of San Antonio
    San Antonio, Texas 78229, United States
  • Center for Clinical Studies
    Webster, Texas 77598, United States
  • University of Utah MidValley Dematology
    Murray, Utah 84107, United States
  • Dermatology Associates
    Seattle, Washington 98101, United States
  • Kurume University Hospital
    Kurume, Fukuoka 830 0011, Japan
  • Hamamatsu University School of Medicine, University Hospital
    Hamamatsu, Shizuoka 431-3192, Japan
  • Tokyo Medical Univ. Hospital
    Shinjuku-ku, Tokyo 160-0023, Japan
  • Osaka City University Hospital
    Osaka, 545-8586, Japan
  • Clinica de Investigacion en Reumatologia y Obesidad S. C.
    Guadalajara, Jalisco 44650, Mexico
  • Consultorio Privado de la Dra. Villanueva
    Guadalajara, Jalisco 44657, Mexico
  • Hospital Universitario Dr. Jose Eleuterio Gonzalez
    Monterrey, N.L. 64460, Mexico
  • CRI Centro Regiomontano de Investigacion S.C.
    Monterrey, Nuevo León 64060, Mexico
  • B&B Investigaciones Medicas, SC
    Mazatlán, Sinaloa 82140, Mexico
  • Derma Norte del Bajío, S.C.
    Aguascalientes, Mexico
  • RM Pharma Specialists S.A. de C.V.
    Distrito Federal, 3100, Mexico
  • Instituto de Investigaciones Aplicadas a la Neurociencia A.C
    Durango, 34000, Mexico
  • Ponce School of Medicine CAIMED Center
    Ponce, PR 00716, Puerto Rico
  • GCM Medical Group, PSC- Hato Rey
    San Juan, PR 00917, Puerto Rico
  • Seoul National University Bundang Hospital
    Seongnam, Geonggi-do 13620, South Korea
  • Inha University Hospital
    Jung-gu, Incheon 22332, South Korea
  • Chonbuk National University Hospital
    Jeonju, Jeon Ra Buk-Do, Korea 54907, South Korea
  • Pusan National University Hospital
    Busan, Korea 49241, South Korea
  • Kyung Pook National University Hospital
    Daegu, Korea 41944, South Korea
  • Chungnam National University Hospital
    Daejeon, Korea 35015, South Korea
  • Seoul National University Hospital
    Seoul, 03080, South Korea
  • Eunpyeong St. Mary's Hospital
    Seoul, 03312, South Korea
  • Konkuk University Medical Center
    Seoul, 05030, South Korea
  • Kyunghee University Hospital at Gangdong
    Seoul, 05278, South Korea
  • Chungang University Hospital
    Seoul, 06973, South Korea
09

References and documents

Publications

  • King B, Mostaghimi A, Shimomura Y, Piraccini BM, Blume-Peytavi U, Sontag A, Dutronc Y, Denning K, Kolodsick J, Lu X, Srivastava A, Sinclair R. Safety of Baricitinib in Adults with Severe Alopecia Areata from Two Phase III Trials Over a Median of 2.3 Years and Up to 4 Years of Treatment. Am J Clin Dermatol. 2025 Jul;26(4):611-622. doi: 10.1007/s40257-025-00932-0. Epub 2025 Apr 11. PubMed 40214720 ↗
  • King B, Ko J, Kwon O, Vano-Galvan S, Piraccini BM, Dutronc Y, Yu G, Liu C, Somani N, Ball S, Mesinkovska NA. Baricitinib Withdrawal and Retreatment in Patients With Severe Alopecia Areata: The BRAVE-AA1 Randomized Clinical Trial. JAMA Dermatol. 2024 Oct 1;160(10):1075-1081. doi: 10.1001/jamadermatol.2024.2734. PubMed 39141364 ↗
  • Craiglow B, Lee YW, Vano-Galvan S, Egeberg A, Dutronc Y, Durand F, Pierce E, Yu G, Chen YF, Mostaghimi A. Improvement in Measures of Quality of Life and Symptoms of Anxiety and Depression in Patients with Severe Alopecia Areata Achieving Sustained Scalp Hair Regrowth with Baricitinib. Dermatol Ther (Heidelb). 2024 Jul;14(7):1959-1968. doi: 10.1007/s13555-024-01208-x. Epub 2024 Jun 21. PubMed 38904749 ↗
  • Senna MM, Kwon O, Piraccini BM, Sinclair R, Ball S, Ding Y, Chen YF, Dutronc Y, King B. Clinical Benefits of Baricitinib Therapy According to Scalp Hair Regrowth in Patients with Severe Alopecia Areata. Dermatol Ther (Heidelb). 2023 Dec;13(12):3209-3220. doi: 10.1007/s13555-023-01063-2. Epub 2023 Nov 22. PubMed 37991697 ↗
  • Ko JM, Mayo TT, Bergfeld WF, Dutronc Y, Yu G, Ball SG, Somani N, Craiglow BG. Clinical Outcomes for Uptitration of Baricitinib Therapy in Patients With Severe Alopecia Areata: A Pooled Analysis of the BRAVE-AA1 and BRAVE-AA2 Trials. JAMA Dermatol. 2023 Sep 1;159(9):970-976. doi: 10.1001/jamadermatol.2023.2581. PubMed 37556146 ↗
  • Piraccini BM, Ohyama M, Craiglow B, Bewley A, Ding Y, Chen YF, Dutronc Y, Pierce E, Durand F, Mostaghimi A. Scalp hair regrowth is associated with improvements in health-related quality of life and psychological symptoms in patients with severe alopecia areata: results from two randomized controlled trials. J Dermatolog Treat. 2023 Dec;34(1):2227299. doi: 10.1080/09546634.2023.2227299. PubMed 37381691 ↗
  • Kwon O, Senna MM, Sinclair R, Ito T, Dutronc Y, Lin CY, Yu G, Chiasserini C, McCollam J, Wu WS, King B. Efficacy and Safety of Baricitinib in Patients with Severe Alopecia Areata over 52 Weeks of Continuous Therapy in Two Phase III Trials (BRAVE-AA1 and BRAVE-AA2). Am J Clin Dermatol. 2023 May;24(3):443-451. doi: 10.1007/s40257-023-00764-w. Epub 2023 Mar 1. PubMed 36855020 ↗
  • King B, Mostaghimi A, Shimomura Y, Zlotogorski A, Choi GS, Blume-Peytavi U, Passeron T, Holzwarth K, Dutronc Y, McCollam J, Yang FE, Stanley S, Wu WS, Sinclair R. Integrated safety analysis of baricitinib in adults with severe alopecia areata from two randomized clinical trials. Br J Dermatol. 2023 Feb 10;188(2):218-227. doi: 10.1093/bjd/ljac059. PubMed 36763878 ↗
  • King B, Ohyama M, Kwon O, Zlotogorski A, Ko J, Mesinkovska NA, Hordinsky M, Dutronc Y, Wu WS, McCollam J, Chiasserini C, Yu G, Stanley S, Holzwarth K, DeLozier AM, Sinclair R; BRAVE-AA Investigators. Two Phase 3 Trials of Baricitinib for Alopecia Areata. N Engl J Med. 2022 May 5;386(18):1687-1699. doi: 10.1056/NEJMoa2110343. Epub 2022 Mar 26. PubMed 35334197 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and European Union (EU), whichever is later. Data will be indefinitely available for requesting.

Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2018 to primary completion in Feb 2021, 28 months.

Results were first posted in Oct 2025, 4 years 7 months after primary completion. A results delay was requested in Feb 2022.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 18, 2018
First posted
Jun 27, 2018
StartActual
Sep 24, 2018
Primary completionActual
Feb 2, 2021
CompletionActual
Jan 29, 2025
Results delay requested
Feb 2, 2022
Results first posted
Oct 1, 2025
Last update
Apr 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 16, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03570749
Collaborators
Incyte Corporation
Responsible party
Sponsor
First posted
Jun 27, 2018
Start date
Sep 24, 2018
Primary completion
Feb 2, 2021
Completion
Jan 29, 2025
Results posted
Oct 1, 2025
Last update
Apr 16, 2026

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Baricitinib

Start the discussion